Docobo technology is used by the Medical University of Vienna to remotely monitor the symptoms of cancer patients undergoing treatment.
The Department of Hematology at the Medical University of Vienna uses Docobo’s DOC@HOME health platform and app. The company’s cancer patients can monitor their symptoms and collect and transmit routine data through remote monitoring from home. Patients use the app on their devices to monitor symptoms, and data is automatically sent to the clinical hub in real time.
Once the data is processed, clinicians are alerted if thresholds are exceeded so they can take action. In addition to these safety measures for daily use, all symptoms are considered and can be discussed during scheduled patient visits.
The use of the Docobo app was born thanks to the successful EU project eSMART. This project demonstrated that the use of telemedicine can lead to significant improvements in standards of care. Between 2014 and 2019, they studied 829 patients, 140 of whom were students at the Medical University of Vienna.
Remote monitoring forms part of patient-reported outcomes (PROs). This supports better care by monitoring treatment progress, enhancing care planning and decision-making, and setting treatment goals.
“Remote monitoring has a positive effect on the survival rate of cancer patients and can identify recurrence more quickly, which could lead to optimal treatment,” said Dr. Simone Lubowitsky from the Medical University of Vienna.
“We also use this app to collect validated and established questionnaires about patient quality of life related to their disease. Based on evidence about cancer and chemotherapy at any time via the app Patients highly value DOC@HOME because it provides access to general information. For clinicians, the app frees up time to care for patients, with all data available at the push of a button. increasing.”
In 2022, Docobo added the ability to virtually monitor breathing rate to its features. The Medical University of Vienna is currently programming and expanding the app to cover other diseases as well, supporting a further step towards personalized medicine and care.